Factors influencing the ratio of free to total prostate-specific antigen in serum

International Journal of Cancer

Volumn 74, Issue 6, 1997, Pages 630-636

  Meyer, Annette ^a   Jung, Klaus ^a,b   Lein, Michael ^a   Rudolph, Birgit ^a   Schnorr, Dietmar ^a   Loening, Stephan A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOANALYSIS; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ECHOGRAPHY; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS;

EID: 0031443553     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971219)74:6<630::AID-IJC13>3.0.CO;2-9     Document Type: Article

References (21)

1. ARCANGELI, C.G., SHEPHERD, D.L., SMITH, D.S., HUMPHREY, P.A., KEETCH, D.W. and CATALONA, W.J., Correlation of percent free PSA with pathologic features of prostatic carcinomas. J. Urol., 155 (Suppl.), 415A (1996).
2. BATES, T.S., REYNAND, J.M., PETERS, T.J. and GINGELL, J.C., Determination of prostatic volume with transrectal ultrasound: a study of intra-observer and inter-observer variation. J. Urol., 155, 1299-1300 (1996).
3. BJÖRK, T., HULKKO, S., BJARTELL, A., DI SANT' AGNESE, A., ABRAHAMSSON, P.A. and LILJA, H., Alpha-1-antichymotrypsin production in PSA- producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology, 43, 427-434 (1994).
4. BUNTING, P.S., A guide to the interpretation of serum prostate-specific-antigen levels. Clin. Biochem., 28, 221-241 (1995).
5. CATALONA, W.J., Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate, 7 (Suppl.), 64-69 (1996).
6. CATALONA, W.J., SMITH, D.S., WOLFERT, R.L., WANG, T.J., RITTENHOUSE, H.G., RATLIFF, T.L. and NADLER, R.B., Evaluation of percentage of tree serum prostate-specific antigen to improve specificity of prostate-cancer screening. J. Amer. med. Assoc., 274, 1214-1220 (1995).
7. EGAWA, S., SOH, S., OHORI, M., UCHIDA, T., GOHJI, K., FUJII, A., KUWAO, S. and KOSHIBA, K., The ratio of tree to total serum prostate-specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer, 79, 90-98 (1997).
8. FILELLA, X., ALCOVER, J., MOLINA, R., GIMENEZ, N., RODRIGUEZ, A., JO, J., CARRETERO, P. and BALLESTO, A.M., Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int. J. Cancer. 63, 780-784 (1995).
9. GUESS, H.A., GORMLEY, G.J., STONER, E. and OESTERLING, J.E., The effect of finasteride on prostate-specific antigen: review of available data. J. Urol., 155, 3-9 (1996).
10. HENDRICKS, W.H., ENGLAND, B.G., GIACHERIO, D.A., OESTERLING, J.E. and WOJNO, K.J., Free to total PSA ratio does not predict extraprostatic spread of prostatic adenocarcinoma. J. Urol., 155 (Suppl.), 369A (1996).
11. JACOBSEN, S.J. and OESTERLING, J.E., Age-specific reference ranges for serum prostate-specific antigen levels. J. clin. Ligand. Assay. 18, 93-97 (1995).
12. JUNG, K., STEPHAN, C., LEIN, M., HENKE, W., SCHNORR, D., BRUX, B., SCHÜRENKÄMPER, P. and LOENING, S.A., Analytical performance and clinical validity of two free-prostate-specific-antigen assays compared. Clin. Chem., 42, 1026-1033 (1996).
13. KAIRISTO, V. and POOLA, A., Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand. J. clin. Lab. Invest., 55 (Suppl. 222), 43-60 (1995).
14. OESTERLING, J.E., JACOBSEN, S.J., KLEE, G.G., PETTERSSON, K., PIIRONEN, T., ABRAHAMSSON, P.A., STENMAN, U.H., DOWELL, B., LÖVGREN, T. and LILJA, H., Free, complexed and total serum prostate-specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J. Urol., 154, 1090-1095 (1995).
15. PARTIN, A.W., CATALONA, W.J., SOUTHWICK, P.C., SUBONG., E.N.P., GASIOR, G.H. and CHAN, D.W., Analysis of percent free prostate-specific antigen (PSA) for prostate-cancer detection: influence of total PSA, prostate volume, and age. Urology, 48, 55-61 (1996).
16. SEMJONOW, A., OBERPENNING, F., BRANDT, B., ZECHEL, C., BRANDAU, W. and HERTLE, L., Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology, 48, 10-15 (1996).
17. STAMEY, T.A., Some comments on progress in the standardisation of immunoassays for prostate-specific antigen. Brit. J. Urol., 79 (Suppl. 1), 49-52 (1997).
18. STEPHAN, C., LEIN, M., JUNG, K., SCHNORR, D. and LOENING, S.A., The influence of prostate volume on the ratio of free to total prostate-specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 79, 104-109 (1997).
19. UICC, TNM Klassifikation maligner Tumoren (4th ed.), pp. 141-165, Springer, Berlin (1992).
20. VASHI, A. and 12 OTHERS, Determination of the "Reflex Range" and appropriate cutpoints for % free PSA in 413 men referred for prostate evaluation using the AxSYM SYSTEM. Urology, 49, 19-27 (1997).
21. YEMOTO, C.M., NOLLEY, R., PRESTIGIACOMO, A.F. and STAMEY, T.A., Free (f) and total (t) PSA density in patients with prostate cancer (CaP) and benign prostatic hyperplasia. J. Urol., 155 (Suppl.), 374A (1996).